Patents Examined by Oluwatosin A Ogunbiyi
  • Lactic acid bacteria, methods and uses thereof
    Patent number: 11285181
    Abstract: The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: March 29, 2022
    Assignee: Biogaia AB
    Inventor: Stefan Roos
  • Modified host cells and hybrid oligosaccharides for use in bioconjugate production
    Patent number: 11285200
    Abstract: Provided herein are host cells capable of producing hybrid oligosaccharides and polysaccharides, wherein said hybrid oligosaccharides and polysaccharides do not comprise a hexose at the reducing end of their first repeat unit. Also provided herein are hybrid oligosaccharides or polysaccharides and bioconjugates which can be produced by the host cells described herein, wherein said bioconjugates comprise a carrier protein linked to a hybrid oligosaccharide or polysaccharide that does not comprise a hexose at the reducing end of its first repeat unit.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: March 29, 2022
    Inventor: Amirreza Faridmoayer
  • Expression of recombinant proteins in pupae
    Patent number: 11278014
    Abstract: The present invention covers means and methods to increase the efficiency of recombinant protein expression, in particular to optimize the industrial production of recombinant proteins in insect pupae, particularly in Trichoplusia ni (T. ni) pupae. Moreover, the present invention is also directed to the pupae itself comprising baculovirus, pupae infected, transformed, transduced or transfected with baculoviruses or bacmids, as well as devices suitable for performing the methods of the present invention.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: March 22, 2022
    Assignee: Alternative Gene Expression, S.L.
    Inventors: José Ángel Martínez Escribano, Carmen Alvarado Fradua, Edel Reytor Saavedra, Miguel Cid Fernandez
  • Compositions and methods for the removal of biofilms
    Patent number: 11274144
    Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: March 15, 2022
    Assignee: Research Institute at Nationwide Children's Hospital
    Inventors: Steven D. Goodman, Lauren O. Bakaletz
  • Bordetella vaccine
    Patent number: 11229690
    Abstract: The present invention provides genetically engineered strains of the Bordetella species to include one or more mutations preventing expression of the gene encoding the Bordetella Sigma Regulator (also referred to as “bsr,” “btrS,” and “brpL”), compositions and vaccines thereof, and the use of such engineered strains in methods to protect against Bordetella spp, including but not limited to Bordetella bronchiseptica, B. pertussis, B. parapertussis, B. homelsii, or B. avium. In some aspects, the present invention provides the Bordetella bronchiseptica strain RB50?bsr, compositions and vaccines thereof, and the use of Bordetella bronchiseptica strain RB50?fer in methods to protect against Bordetella spp, including but not limited to Bordetella bronchiseptica, B. pertussis, B. parapertussis, B. homelsii, or B. avium.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 25, 2022
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Eric T. Harvill, Monica Cartelle Gestal
  • Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, bacillus anthracis and yersinia pestis
    Patent number: 11219686
    Abstract: Bivalent immunogenic compositions against anthrax and plague are disclosed herein. One bivalent immunogenic composition comprises a triple fusion protein containing three antigens, F1 and V from Yersinia pestis and PA antigen from Bacillus anthracis fused in-frame and retaining structural and functional integrity of all three antigens. Another bivalent immunogenic composition comprises bacteriophage nanoparticles arrayed with these three antigens on the capsid surface of the bacteriophage nanoparticles. These bivalent immunogenic compositions are able to elicit robust immune response in a subject administered said the bivalent immunogenic compositions and provide protection to the subject against sequential or simultaneous challenge with both anthrax and plague pathogens.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: January 11, 2022
    Assignee: The Catholic University of America
    Inventor: Venigalla B. Rao
  • Immunotherapy of canine leishmaniasis
    Patent number: 11219677
    Abstract: The present invention provides a method for treating canine leishmaniasis by immunotherapy.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: January 11, 2022
    Inventors: Kwang-Poo Chang, Laura Manna, Raffaele Corso, Bala K. Kolli
  • Multi-subunit vaccines to elicit both MHC- and CD1-restricted T cell responses
    Patent number: 11202823
    Abstract: Provided herein are subunit vaccine compositions comprising a nanocarrier and a lipid antigen, a peptide antigen or combinations thereof that elicit bother a CD1-restricted and an MHC-restricted T cell response in a subject. Methods for making and using the subunit vaccine compositions are also provided.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: December 21, 2021
    Assignee: Northwestern University
    Inventors: Evan A. Scott, Chyung-Ru Wang, Shaobin Shang, Dina Kats
  • Ii vaccine adjuvant
    Patent number: 11179461
    Abstract: The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The present vaccine stimulates an enhanced immune response.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: November 23, 2021
    Assignee: UNIVERSITY OF COPENHAGEN
    Inventors: Peter Johannes Holst, Cyrielle Elyette Fougeroux
  • Engineered bacteria for production and release of therapeutics
    Patent number: 11174486
    Abstract: Some embodiments described herein relate to cells which have been genetically engineered to release a polypeptide when a population of the cells reaches a desired density. In some embodiments, the released polypeptide may be a therapeutic polypeptide. In some embodiments, the therapeutic polypeptide kills tumor cells or which inhibits the growth of tumor cells.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: November 16, 2021
    Assignees: The Regents of the University of California, Massachusetts Institute of Technology
    Inventors: Jeff Hasty, Lev Tsimring, Muhammad Omar Din, Arthur Prindle, Sangeeta Bhatia, Tal Danino
  • Purification of CRM 197 from bacteria
    Patent number: 11174284
    Abstract: The present invention relates to the use of redox agents for purification of the CRM 197 variant of diphtheria toxin. The invention further relates to multi-step purification of CRM 197 from bacterial fermentates.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: November 16, 2021
    Assignee: SCARAB GENOMICS, LLC
    Inventors: Frederick R. Blattner, David Frisch, Charles Landry, John Brandon
  • Virulence attenuated bacteria for treatment of malignant solid tumors
    Patent number: 11166987
    Abstract: The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains for use in a method of treating a malignant solid tumor in a subject.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: November 9, 2021
    Assignee: Universitaet Basel
    Inventors: Simon Ittig, Marlise Amstutz, Christoph Kasper, Guy R. Cornelis
  • Vaccine against infection
    Patent number: 11155585
    Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 26, 2021
    Assignee: INTERVACC AB
    Inventors: Bengt Guss, Lars Frykberg, Margareta Flock, Jan-Ingmar Flock, Karl Olov Zachrisson
  • Vaccine for prevention of necrotic enteritis in poultry
    Patent number: 11154606
    Abstract: In certain embodiments, the present invention provides a poultry vaccine comprising an antigenic protein comprising a PlcC protein unit that is operably linked to a peptide linker that is operably linked to a NetB protein unit, where the vaccine is effective in stimulating a protective cellular and/or humoral immune response to C. perfringens. Methods are also provided for making the vaccine and for vaccinating poultry by administering such a vaccine.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: October 26, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Kenneth Roland, Andrew Diamos, Hugh Mason
  • KBL693 strain and use thereof
    Patent number: 11141444
    Abstract: A strain of Lactobacillus crispatus KBL693 and the use thereof are disclosed. The strain of Lactobacillus crispatus KBL693 (Accession No. KCTC 13519BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects. Thus, the single strain alone can achieve all the purposes of alleviating atopic dermatitis and other allergic diseases and improving inflammatory diseases and autoimmune diseases, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: October 12, 2021
    Assignee: KO Biolabs, Inc.
    Inventors: Woo Ri Ko, June Chul Lee, Tae-Wook Nam, Gwang Pyo Ko, Hyun Ju You, So Yon Yoon, Seok Cheon Song
  • Protective anti-ZIKV vaccine without inducing cross-reactions with dengue
    Patent number: 11136354
    Abstract: The subject application provides a genetically modified recombinant facultative intracellular invasive bacterial pathogen (RFIIBP) or a recombinant attenuated Salmonella vaccine (RASV) strains encoding Zika virus (ZIKV) antigens. These strains exhibit high immunogenicity, complete safety, and attenuation, and are unable to persist or be shed in an infective or viable form. These RFIIBPs and RASVs also exhibit regulated delayed attenuation in vivo, regulated delayed in vivo synthesis of protective ZIKV antigens. Methods of inducing mucosal, systemic and cellular immunities in hosts are also provided and antibodies produced using the disclosed RFIIBPs and RASVs can comprise neutralizing antibodies against ZIKV that do not crossreact with Dengue virus (DENV).
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: October 5, 2021
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventor: Roy Curtiss, III
  • Engineered clostridium botulinum toxin adapted to deliver molecules into selected cells
    Patent number: 11118170
    Abstract: An engineered payload-delivery system includes a target cell binding unit, covalently bound to a pore forming unit, and a payload portion adapted with a region capable of non-covalently binding to the pore forming unit. The pore forming unit is derived from a particular sub-serotype of Clostridium toxin, while the payload region is derived from a different sub-serotype of Clostridium toxin. The disclosed chimeric protein-based composition is capable of specifically delivering payload to neural cells.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: September 14, 2021
    Assignee: The Board of Regents of the University of Nebraska
    Inventors: Benjamin J. Pavlik, Paul Blum, Kevin Van Cott
  • Treatment of warts
    Patent number: 11116808
    Abstract: Disclosed herein are compositions having standardized potencies for use in the treatment of warts. Methods of treating a common wart comprising administering one or more intralesional injections of compositions having standardized potencies to a patient in need thereof are also disclosed. Further disclosed are methods of treating a non-common wart administering one or more intralesional injections of compositions having standardized potencies to a patient in need thereof.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: September 14, 2021
    Assignee: Nielsen Biosciences, Inc.
    Inventor: H. Stewart Nielsen, Jr.
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 11110161
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: September 7, 2021
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Method for high level production of CRM
    Patent number: 11098089
    Abstract: The present invention provides an improved method for the production of CRM197 with high yield using engineered Corynebacterium diphtheria strain having an increased copy number of the CRM197 gene, wherein the method comprises growing the strain in media free of animal-derived components with one or more amino acids.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: August 24, 2021
    Inventors: Balamurali Masilamani, Rajan Sriraman, Mandar Shirish Dixit, Deviprasanna Chakka, Satyam Naidu Sureddi, Ramesh Venkat Matur, Narender Dev Mantena, Mahima Datla